GO
Loading...

Mad Mail: Medco or Express Scripts?

Tuesday, 18 Dec 2007 | 7:21 PM ET
Mad Mail
Mad Money host Jim Cramer answers your emails.

Mr. Cramer: On Monday you highlighted “visibility stocks,” one of which was Transocean. You admitted that every time oil goes down a buck the stock takes a hit, but you insist it’s undeserved because of their long-term contracts. I agree with you in theory, but in a stock that hasn't paid a dividend in nearly six years, why should I care about reality when perception rules the value of my portfolio? I'm a young person - still a student - and a new investor, and this question is applicable to a number of stocks. I'd appreciate it if you could explain how to deal with this paradox…educate me, Jim! --Mark

Cramer says: Transocean is a pure growth stock. The company doesn’t want to pay a dividend. It just wants to keep returning capital by making the stock go up. Yes, conservative investors want a dividend. But RIG has growth, and “growth is what the market really loves.”

Dear Jim: Last night, you recommended Medco Health Services and it looks intriguing. However, I already own Express Scripts and have been rewarded there. Does it make any sense to switch to MHS, or add a position in MHS, or would you recommend increasing my investment in ESRX? --Jan

Cramer says: “ESRX is really good. I would not switch. I like Medco a little bit more. But I owned Express Scripts and made a bit amount of money in my charitable trust.”

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

  Price   Change %Change
ESR
---
RIG
---

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.